Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Davis, California 95616


Purpose:

The objective of this study was to rule out a greater than 10% incidence of hypersensitivity to Vitrase following a single intradermal injection of 3 USP units Vitrase. Less than or equal to 10% hypersensitivity response was considered acceptable.


Criteria:

Inclusion Criteria: - Avoid disallowed meds throughout study Exclusion Criteria: - Known hypersensitivity to hyaluronidase and/or bee sting - Atopic individuals assessed by med history - Topical/systemic corticosteroids within 30 days - Concurrent use of antihistamines or anti-inflammatory during study - Active or chronic disease likely to affect immune function - History of alcohol/drug abuse within 6 months


NCT ID:

NCT00198419


Primary Contact:

Study Director
Lisa R Grillone, PhD
ISTA Pharmaceuticals, Inc.


Backup Contact:

N/A


Location Contact:

Davis, California 95616
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 18, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.